Results 71 to 80 of about 5,389 (186)

Jaceidin Suppresses Melanoma Metastasis by Modulating ERK, JNK Pathways and Extracellular Matrix Degradation Proteins

Journal of Cellular and Molecular Medicine, Volume 30, Issue 4, February 2026.
ABSTRACT Metastatic melanoma, marked by its poor prognosis and frequent recurrence, is a particularly aggressive skin cancer. Jaceidin, a compound derived from flavonoids abundant in common fruits and vegetables, has attracted interest for its potential anti‐cancer properties.
Mu‐Kuei Shieu, Hui‐Ju Yang, Chia‐Chieh Lin, Min‐Yun Kao, Hsin‐Yu Ho, Yu‐Sheng Lo, Yi‐Ching Chuang, Yuan‐Ting Yang, Ming‐Ju Hsieh   +8 more
wiley   +1 more source

BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer

Cell Death and Disease
Metastatic BRAF V600E colorectal cancer (CRC) carries an extremely poor prognosis and is in urgent need of effective new treatments. While the BRAFV600E inhibitor encorafenib in combination with the EGFR inhibitor cetuximab (Enc+Cet) was recently ...
Laura J. Jenkins, Ian Y. Luk, Fiona Chionh, Tao Tan, Kristen Needham, Jamieson Ayton, Camilla M. Reehorst, Natalia Vukelic, Oliver M. Sieber, Dmitri Mouradov, Peter Gibbs, David S. Williams, Niall C. Tebbutt, Jayesh Desai, Frédéric Hollande, Amardeep S. Dhillon, Erinna F. Lee, Delphine Merino, W. Douglas Fairlie, John M. Mariadason   +19 more
doaj   +1 more source

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries

Cancer Medicine, 2021
Background Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. Methods This study included all adult patients who received BRAF inhibitors (vemurafenib, dabrafenib ...
Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos deLima, Jill S. Barnholtz‐Sloan, Guilherme H. Oliveira, Afshin Dowlati, Sadeer Al‐Kindi   +10 more
doaj   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer

The Journal of Clinical Investigation
BRAFV600E-mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis. The combination of anti-BRAF/anti-EGFR (encorafenib/cetuximab) treatment for patients with BRAFV600E-mutant mCRC improves clinical benefits; unfortunately, inevitable
Jiawei Wang, Huogang Wang, Wei Zhou, Xin Luo, Huijuan Wang, Qing Meng, Jiaxin Chen, Xiaoyu Chen, Yingqiang Liu, David W. Chan, Zhenyu Ju, Zhangfa Song   +11 more
doaj   +1 more source

Safety and efficacy of encorafenib–cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study

ESMO Real World Data and Digital Oncology
Background: Dual blockade therapy encorafenib–cetuximab (EC) was recently established as the standard of care for second- or third-line treatment for BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients based on BEACON phase III study results ...
A. Fernández-Montes, J. Ros, P. García-Alfonso, B. Graña, E. Brozos-Vázquez, M. Melián, A.Mª Jiménez-Gordo, E. Martínez de Castro, I. Busquier, A. Ferrández Arias, C. Grávalos, M. Covela, A. Ruíz-Casado, E. González-Flores, Mª J. Safont, J.Mª Cano, C. Alonso-López, Mª J. Gómez-Reina, O. Donnay, J.L. Manzano-Mozo, P. Sampedro Domarco, E. Falcó, N. Rodríguez, C. García-Benito, E. Aranda   +24 more
doaj   +1 more source

Novel process for the preparation of methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3­ (methanesulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino] propan-2­yl}carbamate [PDF]

, 2022
: The present invention relates to a novel process for the preparation of methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3­(methanesulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2­yl}carbamate represented by the following ...
, MSN Laboratories Private Limited, R&D Center
core   +1 more source

A Robust Immunohistochemistry‐Based Classification for BRAF V600E‐Mutant Colorectal Cancer With Clinical Implications

Cancer Science, Volume 117, Issue 1, Page 246-256, January 2026.
This study develops an immunohistochemistry (IHC)‐based classification system for BRAF V600E‐mutant colorectal cancer, enabling practical stratification into iBM1 and iBM2 subtypes using CD8 and ARHGEF17 markers. The IHC‐defined subtypes demonstrated concordance with transcriptomic BM1/BM2 classifications and reflected distinct molecular and immune ...
Chao Liu, Yuli Ruan, Tong Wu, Xindi Luan, Yue Ma, Hong Wang, Tianjiao Dang, Yiwen Ou, Bojun Wang, Chunhui Zhang, Hongxue Meng, Yanqiao Zhang   +11 more
wiley   +1 more source

Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma☆

ESMO Real World Data and Digital Oncology
Background: Understanding of comparative efficacy of treatments can inform clinical decision-making. This study compared overall survival (OS) and progression-free survival (PFS) across patients with metastatic BRAFV600-mutant melanoma initiating ...
G.K. In, K. Chen, G. Sajeev, R. Simpson, S. Kalia, D. Christensen, D. Liu, N. Rezai, A. di Pietro, J. Signorovitch   +9 more
doaj   +1 more source

Circulating hsa‐miR‐29c‐3p and VEGF‐A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Metastatic colorectal cancer (mCRC) patients who progress on oxaliplatin‐based chemotherapy benefit from second‐line treatment with FOLFIRI plus aflibercept. However, the absence of validated biomarkers for antiangiogenic therapies remains a challenge. Circulating levels of VEGF‐A and 13 miRNAs were analysed in 154 elderly mCRC patients.
Marta Toledano‐Fonseca, María Teresa Cano‐Osuna, Elena Élez, Javier Soto‐Alsar, David Páez, Ana Fernández‐Montes, Begoña Graña, Antonieta Salud, Alfonso Yubero, Ismael Macías, Guillermo Quintero, Carlos López‐López, Teresa Fernández‐Rodríguez, María Victoria García‐Ortiz, Javier Sastre, Pilar García‐Alfonso, Antonio Rodríguez‐Ariza, Enrique Aranda, on behalf of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)   +18 more
wiley   +1 more source